Savara Inc (SVRA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$101.04M

Year ended 2025-12-31

-$110.38M

Trailing 12 months to 2026-06-30

2010-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$101.04M	n/m	2026-03-13, From 2025-01-01
2024-12-31	-$89.09M	n/m	2026-03-13, From 2024-01-01
2023-12-31	-$51.06M	n/m	2025-03-27, From 2023-01-01
2022-12-31	-$34.55M	n/m	2024-03-07, From 2022-01-01
2021-12-31	-$40.08M	n/m	2023-03-30, From 2021-01-01
2020-12-31	-$39.84M	n/m	2022-03-30, From 2020-01-01
2019-12-31	-$45.12M	n/m	2021-03-10, From 2019-01-01
2018-12-31	-$39.27M	n/m	2020-03-12, From 2018-01-01
2017-12-31	-$28.23M	n/a	2019-03-13, From 2017-01-01
No annual figure between 2013-12-31 and 2017-12-31.
2013-12-31	-$17.79M	n/m	2014-03-26, From 2013-01-01
2012-12-31	-$13.92M	n/m	2014-03-26, From 2012-01-01
2011-12-31	-$13.47M	n/m	2013-03-19, From 2011-01-01
2010-12-31	-$8.34M	n/a	2012-03-08, From 2010-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Savara Inc (SVRA)	2025-12-31	-$101.04M	n/m
Heron Therapeutics, Inc. (HRTX)	2025-12-31	-$27.59M	n/m
Macrogenics Inc (MGNX)	2025-12-31	-$81.04M	n/m
Assembly Biosciences, Inc. (ASMB)	2025-12-31	-$41.09M	n/m
Phathom Pharmaceuticals, Inc. (PHAT)	2025-12-31	-$166.78M	n/m
Damora Therapeutics, Inc. (DMRA)	2025-12-31	-$6.73M	n/m
Verastem, Inc. (VSTM)	2025-12-31	-$137.51M	n/m
Nature's Sunshine Products Inc (NATR)	2025-12-31	$35.32M	+39.6%
Perspective Therapeutics, Inc. (CATX)	2025-12-31	-$82.48M	n/m

Compare SVRA, HRTX, MGNX, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗